SS37: Image-Guided Therapy II

Monday, June 13
4:45 PM–6:15 PM

Location: 30B (San Diego Convention Ctr)

Education: Scientific CE Session

Room: 30B

Moderators: Seigo Kinuya, MD, PhD; Gi Jeong Cheon, MD

No. 247
4:45 PM
Targeted radionuclide therapy of malignant tumors using [18F] Fluorodeoxyglucose (FDG): A Phase 1 dose escalation clinical trial
D. Paul*,1 S. Vallabhajosula,2 G. Cristina,1 J. Rini,3 A. Kapur,1 M. Ghaly,4 E. Ben Levi,3 C. Palestro,5 L. Wang,1 J. Antony,1 P. Kamvosoulis,6 H. Gaballa,1 E. Connelly,1 B. Cox4; 1Monter Cancer Center, Lake Success, NY, 2Nuclear Medicine, Weill Cornell Medical College, New York, NY, 3Diagnostic Imaging Center For Advanced Medicine, Lake Success, NY, 4Radiation Medicine, Lake Success, NY, 5Long Island Jewish Hospital, New Hyde Park, NY, 6Long Island Jewish Hospital, New Hyde Park, NY 11042, NY

No. 248
4:57 PM
FDG-PET/CT to predict outcome of first-line chemotherapy plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer
E. Usmanij*,1 T. Natroshvili,1 J. Timmer-Bonte,2 M. van der Drift,3 W. J. Oyen,1 J. Bussink,4 L. De Geus-Oei5; 1Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, Netherlands, 2Oncology, Radboud University Medical Center, Nijmegen, Netherlands, 3Pulmonary Diseases, Radboud University Medical Center, Nijmegen, Netherlands, 4Radiation Oncology, Radboud University Medical Center, Nijmegen, Netherlands, 5Radiology, Leiden University Medical Center, Rotterdam, Netherlands

No. 249
5:09 PM
Correlation of Tumor Heterogeneity Assessed in 68Ga-HBED-CC-PET (PSMA-Ligand) with Clinical Response After 223Ra-Dichloride-Therapy in Patients with Bone Metastases of Prostate Carcinoma
B. Kreppel*,1 H. Ahmadzadehfar,1 M. Essler,1 N. Zsoter,2 L. Papp,2 F. C. Gaertner,1 R. A. Bundschuh,1 L. Thomas1; 1Department of Nuclear Medicine, Universitaetsklinikum Bonn, Bonn, Germany, 2Mediso Medical Imaging Systems Ltd., Budapest, Hungary

No. 250
5:21 PM
Imaging of chemokine receptor 4 expression in neuroendocrine tumors in comparison to DOTATOC and FDG PET/CT
R. A. Werner*,1 A. Weich,2 H. Wester,3 M. Scheurlen,2 T. Higuchi,1 S. Samnick,1 M. Rudelius,4 A. K. Buck,1 K. Herrmann,1 C. Lapa1; 1Department of Nuclear Medicine, University Hospital Wuerzburg, Würzburg, Germany, 2Department of Internal Medicine II, University Hospital Wuerzburg, Würzburg, Germany, 3Scintomics GmbH, Fürstenfeldbruck, Germany, 4Institute for Pathology, University Wuerzburg, Würzburg, Germany

No. 251
5:33 PM
[68Ga]-Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience
C. Lapa*,1 K. Lückerath,1 M. Rudelius,1 A. Schirbel,1 S. Samnick,1 T. Pelzer,1 A. K. Buck,1 S. Kropf,2 H. Wester,3 K. Herrmann1; 1Würzburg University Hospital, Würzburg, Germany, 2Scintomics, Fürstenfeldbruck, Germany, 3Technische Universität München, München, Germany

No. 252
5:45 PM
In vivo Molecular Imaging and Radionuclide (188Re) Therapy of Cervical Cancer Transfected with a Lentivirus Expressing Sodium Iodide Symporter using human Telomerase Reverse Transcriptase Promoter
M. Zhang*, R. Guo, S. Shi, B. Li; Department of Nuclear Medicine, Rui Jin Hospital, Shanghai, China

No. 253
5:57 PM
Comparison of 99mTc-MDP bone scintigraphy (visual and automatic analysis with Exini) and 68Ga-PSMA PET/CT for staging of bone metastases in patients with prostate carcinoma undergoing therapy with 223Ra-dichlorid
L. Thomas*, C. Balmus, H. Ahmadzadehfar, F. C. Gaertner, R. A. Bundschuh; Department of Nuclear Medicine, Universitaetsklinikum Bonn, Bonn, Germany

Speakers